Precursor B-acute lymphoblastic leukemia (pB-ALL) is a heterogeneous disease and multiparameter flow cytometry, molecular genetics, and cytogenetic studies have all contributed to classification of subgroups with prognostic significance. Recently, gene expression microarray technology has been used to investigate lymphoblastic leukemias, demonstrating that known and novel pB-ALL subclasses can be separated on the basis of gene expression profiles. The strength of microarray technique lays in part in the multivariate nature of the expression data. We propose a parallel multiparametric approach based on immunophenotypic flow-cytometry expression data for the analysis of leukemia patients. Specifically, we tested the potential of this approach on a data set of 145 samples of pediatric pB-ALL that included 46 samples positive for mixed lineage leukemia (MLL) translocations (MLL+) and 99 control pB-ALLs, negative for this translocation (MLLÀ). The expression levels of 16 marker proteins have been monitored by four-color flow cytometry using a standardized diagnostic panel of antibodies. The protein expression database has been then analyzed using those univariate and multivariate computational techniques normally applied to mine and model large microarray data sets. Marker protein expression profiling not only allowed separating pB-ALL cases with an MLL rearrangement from other ALLs, but also demonstrates that MLL+ leukemias constitute a heterogeneous group in which MLL/ AF4 leukemias represent a homogenous subclass described by a specific expression fingerprint.
Introduction
Precursor B-acute lymphoblastic leukemia (pB-ALL) is a heterogeneous disease with respect to both its biological characteristics and clinical outcome. In past years, intensive research work allowed the identification of several molecular rearrangements and chromosomal abnormalities that contributed to a deeper understanding of pB-ALL variable biological and prognostic behavior. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] Nowadays, in most clinical centers, immunophenotypic characterization using flow cytometry is the core diagnostic instrumentation to distinguish leukemia subclasses using a panel of phenotypic markers. 3, [11] [12] [13] Recently, gene expression microarray technology and computational analysis of expression data have been applied to investigate lymphoblastic leukemias. Using microarray expression profiling, Armstrong et al 14 demonstrated that pB-ALL with a rearranged mixed lineage leukemia (MLL) gene can be separated from other ALL without this rearrangement and supported the distinction of MLL with a robust gene expression profile. Similarly, Yeoh et al 15 distinguished several known leukemia classes on the basis of expression profiles and identified a new group of leukemias characterized by a peculiar expression pattern. These latter studies strongly support the notion that specific chromosomal translocations result in a distinct type of lymphoblastic leukemia. In addition, genes coding for known diagnostic marker proteins, routinely applied in immunophenotyping of pB-ALL, are among the highest discriminating transcripts in separating different leukemia types. Results obtained by transcriptional profiling have been compared with expression data of marker proteins from flowcytometry analysis. However, this latter comparison is hampered by the lack of quantitative values, as flow-cytometry information is often not fully exploited or analyzed in a simplified and qualitative manner.
Since the strength of microarray-based-analysis/classification of leukemias lays in part in the objective, multivariate computational handling of expression data, we propose a parallel multiparametric analysis of immunophenotypic flowcytometry data in leukemia patients. With this approach, we aim to confront leukemia analysis based on multivariate gene expression data with an investigation based on multivariate marker protein expression and to create an objective tool for immunophenotypic leukemia subclassification.
The potential of this approach has been tested on a data set of 145 samples of pediatric pB-ALL, including 46 samples positive for MLL translocations (MLL+) and 99 control pB-ALLs negative for this translocation (MLLÀ). The expression levels of 16 marker proteins have been monitored by four-color flow cytometry and quantified in terms of mean equivalents of soluble fluorochrome (MESF) and coefficients of variation (CV). A patient cohort similar to that of Armstrong et al 14 was analyzed. The experimental setup, in conjunction with the data mining approach, demonstrates that not only parallel antigen expression profiling allows separating precursor B-ALL cases with an MLL rearrangement from other ALLs, but also that MLL+ leukemias constitute a heterogeneous group with MLL/AF4 leukemias representing a well-defined subclass described by peculiar antigen expression fingerprints.
Materials and methods

Patients and samples
A retrospective analysis has been performed on a total of 145 children diagnosed as suffering from pB-ALL. We included 46 patients who were diagnosed for an MLL rearrangement between May 1995 and June 2001. As a control group, we selected 99 consecutively diagnosed pB-ALL samples that were negative for MLL.
Among MLL patients, 26 are infants (aged o1 year at diagnosis) and 20 noninfants, while in the control group five infants and 94 noninfants, patients are present.
Immunophenotypic and genetic studies have been performed at diagnosis on bone marrow (BM) samples in all but 14 individuals studied, the remaining 14 patients being infants showing hyperleukocytosis with more than 80% of blast cells. In these cases, peripheral blood samples have been used for the immunophenotypic and genetic analysis.
Immunophenotypic studies
Immunophenotypic studies have been performed by flow cytometry using a direct immunofluorescence technique with four-color combinations of monoclonal antibodies (MoAbs). The panel of monitored markers is routinely employed for diagnosis of B-lineage acute leukemias at the AIEOP Reference Laboratory for Immunophenotypic 17 Studies of the University of Padova. In particular, 0.5 Â 10 6 cells in a final volume of 100 ml have been used in each analysis and MoAbs, directly conjugated with fluorescein isothiocyanate (FITC), phycoerythrin (PE) and both PE-Texas red (ECD) and PE-cyanine 5 (PECy5) fluorochrome tandem conjugates have been combined in each tube. The MoAb fluorochrome combinations used in the present study have been obtained from Coulter-Immunotech (Miami, FL, USA; CD10-FITC, CD66c-FITC, CD33-PE, CD22-PE, CD135-PE, CD13-PECy5, CD38-PECy5, CD19-ECD, CD3-ECD, CD24-FITC and NG2-PE), Becton Dickinson (San Jose, CA, USA; CD15-FITC, CD34-PE, CD20-PE, CD8-PE), Caltag Laboratories (San Francisco, CA, USA; CD4-FITC, CD65-FITC, CD45-PECy5, HLADR-PECy5), Myltenyl (Bergisch Gladbach, Germany; CD133-PE).
The sample processing and instrument setup have been performed according to standard operating protocols and procedures previously described. 16, 17 An immunological gate including all blast cells was established in all tube combinations based on the expression of CD19. A dotplot of side scatter with logarithmic amplification vs CD19 was used to construct the immunological gate. For immunological gating, CD19 instead of the more commonly applied CD45 12 was chosen since CD45 expression may be low or negative in a large percentage of ALL of B-cell origin. By using the CD19 gating strategy, all blast cells are included and the percentage of normal B cells resulted not significant. In fact, the presence of normal B cells is routinely evaluated using the CD19/CD34/CD45 combination and the CD19-positive cells with normal expression of CD45 and negative for CD34 resulted lower than 5% in the gated populations. 16, 17 Once the blast population was selected, the expression level of each monitored MoAb has been analyzed in predetermined fixed combinations of MoAbs using for each MoAb only one fluorochrome to avoid possible bias related to utilization of different MoAb combinations or different fluorochromes for the same antibody. 17 To further reduce the impact of different fluorochrome behavior, the use of ECD-conjugated MoAbs was limited to the immunological gate (for CD19 or CD3).
The antigen expression has been quantified by two values, the mean fluorescence intensity (MFI) and the CV, using the CoulterImmunotech System II software, thus overcoming arbitrary negative/positive calls. MFI values have been converted into molecules equivalent of soluble fluorochrome (MESF) employing a calibration beads set (DAKO Fluorospheres reagent kit, Glostrup, Denmark). This kit contains a set of five populations of standardized microbeads having different fluorescence intensities with assigned MESF values and one blank reference population. Entrapped in the beads is a combination of fluorochromes that allows the simultaneous excitation from all channels utilized. A calibration plot, to convert MFI into MESF values, is built, employing the same instrumentation setting, for example, PMT amplification and compensation settings, as used for patient samples analysis with the routine marker panel. Compensation settings were tested before data acquisition using the CD4FITC/CD8PE/CD3ECD/CD45PECy5 combination. This combination is used as internal control for instrumentation setup using normal T lymphocytes, always present in the samples. In fact, the use of CD4FITC (this antigen is expressed at intermediate levels in T lymphocytes and at low levels in monocytes and is used conjugated with a weak fluorochrome), CD8PE (bright antigen conjugated with bright fluorochrome) CD45PECY5 (different intensities in various subpopulations) guarantees the correct instrument compensation and antigen detection independent of their level of expression.
Genetic studies
Specific chromosomal aberrations have been identified through molecular studies (ie RT-PCR assays) according to the BIOMED-1 protocols. In particular, BM samples were collected at diagnosis in the reference laboratory at the University of Padova. Total RNA was isolated using RNAzol-B reagent (TEL-TEST, Inc., Duotech, Milan, Italy), according to manufacturer's protocols. An independent PCR reaction was performed with shifted primers for confirmation of each positive result. The ABL expression was assessed to determine the quality of cDNA and the efficacy of reverse transcription. PCR reaction products were analyzed by electrophoresis (2% agarose gels) and stained with ethidium bromide.
Cytogenetic analysis involved standard karyotyping with Qbanding and FISH. Evaluation of both standard karyotyping and FISH considered at least 10 mitosis per sample. FISH analysis was performed on interphase nuclei and where possible on metaphases, using an MLL probe (Vysis).
Computational methods
The database of the quantitative data for marker expression levels (MESFs) and CVs of all patients has been explored using standard univariate and multivariate computational procedures. In particular, univariate nonparametric hypothesis tests (eg Mann-Whitney rank test) have been applied to identify key variables and expression fingerprints able to discriminate different phenotypes. Univariate procedures tackle the identification of the most informative markers by focusing on whether measurements taken from two different populations of samples behave statistically different. For the analysis of more than two populations or groups, we performed nonparametric group comparisons (eg, Kruskal-Wallis test, a nonparametric version of one-way analysis of variance) with an upper bound on the probability that any comparison will be incorrectly found significant.
Principal component analysis (PCA), a multivariate projection method, has been used as an unsupervised technique to describe globally relation among the different samples through the corresponding expression levels without losing the experimental information contained in the high-dimensional database. PCA allows reducing the dimensionality of complex data and displaying the structure of sample interactions on a reduced space through the transformation of the original variables into a set of linear combinations, the principal components (PCs), with special properties in terms of variances. 18 PCs are derived from a transformation of the original data based on computing and analyzing the data covariance matrix, its eigenvalues and corresponding eigenvectors organized in descending order. PCs are then linearly independent and in decreasing order according to decreasing information content. This allows a straightforward reduction of the data dimensionality by discarding the feature elements with lower information content. Thus, original highdimensional data can be optimally transformed to data patterns in a feature space with lower dimensionality. Singular value decomposition, the algorithm used in this work, or other decomposition methods can be applied to perform PCA after column standardization. Theoretical aspects will be omitted since several texts cover the calculation of the PCs in details. 18 Linear discriminant analysis (LDA) has been finally applied to give proof of concept on how the various markers can be used for the classification of the database samples. A leave-one-out crossvalidation procedure has been incorporated into the discriminatory analysis to improve the classification robustness. 19 The number of markers building the classifier has been sequentially increased to form more complex models until all variables have been included. At each step, the number of misclassified samples has been quantified to determine classification performance, sensitivity, and selectivity for the given classifier.
Results and discussion
Among the 46 childhood pB-ALL cases positive for an MLL translocation, 13 infants and 17 noninfants (for a total of 30 cases, 65%) were shown to carry a t(4;11) translocation. Translocation t(9;11), t(10;11), and t(1;11) have been detected in three (6%), one (2%) and one (2%) patients, respectively. Other 11q23 translocations identified by FISH and negative for t(4;11) by RT-PCR have been found in the remaining 11 cases.
The marker protein expression levels in leukemic cells from patients diagnosed with pB-ALL bearing an MLL translocation have been compared to those of individuals diagnosed with pB-ALL not involving MLL aberrations. Specifically, 32 variables (protein expression values quantified in terms of 16 MESFs and 16 CVs) have been used to monitor 99 patients with childhood ALL negative for the MLL translocation (denoted as MLLÀ), used as a control group, and 46 cases with the MLL translocation (denoted MLL+). First, Mann-Whitney hypothesis tests, a nonparametric version of the classical t-test, have been applied to these two populations to determine whether there were markers, among the 16 tested, whose expression pattern correlated with the presence/absence of an MLL translocation. For the 145 samples tested, 21 variables result statistically discriminating between MLL+ and MLLÀ phenotypes, given a significance level of 0.01. In Table 1 , these parameters are ordered according to the P-value for the null hypothesis that all samples are drawn from the same population or their power in discriminating the two groups. In particular, 12 variables present lower values in MLL+ as compared with MLL-ALLs, while nine are relatively higher in MLL+ ALLs. MLL+ cases are characterized by a higher expression (MESF) of NG2, CD45, CD133, and CD15, and lower expression for CD10, CD24, CD22, CD66c, HLADR, CD20 and CD34. It is worth noting that most of the discriminating markers (eg CD10, CD24, CD22, NG2, CD45, and CD133) correspond to modulated genes in the microarray profiling study.
14 MLL+ individuals show a protein expression profile markedly different from that of MLL-ALL also with respect to the distribution of the expression (CVs). Indeed, NG2, CD15, CD65, CD24, and CD133 show heterogeneous levels of expression (higher values of CV) in MLL+ cases, while the expression distribution of CD45, CD66c, CD10, CD20, and CD38 is more homogeneous (lower CV values) compared to MLL-cases. Figure 1 illustrates the distribution patterns of CD24, CD45, and CD65 antigen expression. MLL-cases show a more homogenous CD24 and CD65 expression than MLL+ cases (higher CV values) while expression levels (MESF) are similar. Marker CD45 shows an inverse relation between MESF and CV values; MLL-cases are characterized by low CD45 MESF values with a high CV, while MLL+ samples have higher MESF values and lower CV values for CD45. These findings demonstrate that CV, a peculiar parameter of immunophenotypic studies that varies independently of the level of expression, represents a valuable descriptor for discriminating between different types of leukemia.
In addition, flow-cytometry values indicate that not only the expression level (MESF) but also the expression distribution (CV) in particular antigens CD24 and CD65 largely differs between MLL+ and MLL-cases. Parallel to the identification of peculiar class markers through a univariate method, PCAs has been applied, as an unsupervised method, to explore the two populations in the high-dimensional, multivariate space defined by all 32 variables. The coordinates of the first three PCs (accounting for the 79.6% of the total variance) have been used to project and cluster all samples in a lower-dimensional space directly calculated from the original protein expression data. As shown in Figure 2 , when all the 32 variables are used to derive the PCA projection, two major, although not completely separated, groups of samples can be identified, one group corresponding to MLL+ leukemias (green dots), the other representing MLL-individuals (blue dots). However, the heterogeneous distribution of MLL+ samples in the PCs space seems to suggest the presence of two distinct MLL+ clusters of samples, one more similar and mixed to the MLL-population and another further separated and distinct from MLL-ALL cases. Indeed, as demonstrated in Figure 2 , the separated MLL+ group comprises samples corresponding to the t(4;11)+ cases (indicated as MLL/ AF4), whose protein profiles characterize as a tight, segregated population. The distinction between MLL/AF4 and other MLL+ (Figure 3a) , intermediate levels in MLL+/t(4;11)- (Figure 3b) , and low expression detected in MLL- (Figure 3c ). In Figure 4 , NG2 raw expression data in all 145 individuals are illustrated. MESF and CV values are represented in a bar graph with MLL/AF4 individuals in red, MLL+/t(4;11)-samples in green, and MLL-cases in blue. Given the presence of more than two populations, nonparametric independent group comparison has been applied for the identification of peculiar markers able to distinguishing simultaneously MLL/AF4, MLL+/t(4;11)-, and MLL-categories. In particular, a two-step procedure, consisting in a nonparametric analysis of variance followed by a multiple comparison test, has been implemented. 19 The multiple test procedure is designed to compare all possible pairs of means and determine which pairs are significantly different under the selected probability level (ie 0.01). Although this technique resembles multiple pairwise comparisons, the difference is that the probability levels are Computational flow-cytometry analysis of pB-ALL subgroups De Zen et al controlled by a critical value (eg Tukey's significant difference criterion) accounting for the multiple tests and providing an upper bound on the probability that any comparison will be incorrectly found significant (type I error), given the number of comparisons at the significance level. Table 3 lists the 21 variables for which the alternative hypothesis -that means are not equal is true in at least two populations. In particular, NG2 expression level (ie MESF value) is the only variable that allows separating all the three populations into three statistically different classes, characterized by high NG2 expression levels in MLL/AF4, intermediate in MLL+/t(4;11)-, and low in MLL-samples. All the other 20 markers allow simultaneously discriminating only one or two groups from the remaining. In particular, the expression of NG2 is more heterogeneous (ie higher CVs) in the MLL/AF4 group than in samples with other MLL rearrangements or negative for MLL translocations. The fact that NG2 present a specific profile for the t(4;11) translocation is in perfect agreement with previously published studies describing this marker as highly specific but not sensitive in detecting MLL+ cases. [20] [21] [22] [23] Considering other discriminating markers, it can be noted that MLL/AF4 and MLL+/t(4;11)-patients present a low expression of CD10 compared to ALLs with no MLL rearrangement, but this parameter cannot statistically discriminate the two subgroups with MLL translocations, although it allows identification of MLL/AF with high sensitivity and specificity (Table 4) . CD24 represents an interesting case since it clearly indicates the independency between MESF and CV values. Indeed, this marker simultaneously presents very low expression levels (ie MESFs) and very high CV values in MLL/AF4 leukemias. This finding helps explaining the previous published observation describing two different blast cell populations in t(4;11) leukemia, one positive for CD24 and the other negative. [24] [25] [26] [27] However, although reported in other papers, 28 this is not a characteristic of MLL rearrangements in toto, as this type of leukemia can present cases where high expression values of CD24 are accompanied by homogeneous distributions of the marker level (as in MLL-cases). CD22 and CD65 represent two other interesting markers. As regards to CD65, while similarly expressed in all cases, it was found to characterize MLL/AF4 patients with a highly heterogeneous pattern thus resulting, with its CV profile, a statistically discriminant variable for MLL/AF4 identification. On the contrary, CD22 is characterized by comparable values of CV in the three classes, while expressed at low, intermediate, and high levels in MLL/AF4, MLL+/t(4;11)-, and MLL-, respectively. Unfortunately, a light overlapping between MESF values in MLL/AF4 and MLL+/t(4;11)-does not allow to statistically define CD22 as an MLL/AF4 marker.
A supervised learning system based on LDA has been designed and tested to give proof of concept on how the various markers can be used for the classification of the database samples. Since no training or test sets are a priori defined, the prediction ability and stability of the classifier has been determined through a leave-one-out crossvalidation procedure. 19 Furthermore, the number of markers building the classifier has been sequentially increased to form more complex Table 3 Variables that are statistically discriminating between MLL/AF4, MLL+/t(4;11)À, and MLL-phenotypes 
À01
Computational flow-cytometry analysis of pB-ALL subgroups De Zen et al models until all variables have been included. In particular, 32 different classifiers have been created using increasing numbers of markers starting from the top ranking in the discriminating list of Table 3 (eg only NG2 MESF; NG2 MESF and CD10 MESF; NG2 MESF, CD10 MESF, and NG2 CV; etc). In each model, the number of correctly classified and misclassified samples has been determined for the calculation of overall classification, sensitivity, and selectivity on the three classes of the classifier over the 145 different learning and crossvalidation sessions. Table 4 lists the classification performances of the 32 LDA classifiers created using increasing numbers of markers. Although a classification rate higher than 85% of correctly classified samples can be achieved using the first seven markers of Table 3 , a better performance, intended as a combination of classification rate and specificity and sensitivity for all classes, can be obtained using all 21 discriminating markers. In this case, no MLL/AF4 samples have been misclassified, one MLL+/t(4;11)-sample has been classified as MLL/AF4, eight MLL-samples were predicted as MLL+/t(4;11)-, while one patient negative for MLL translocation was erroneously recognized as an MLL/AF4. Using this new approach, all MLL rearrangements and MLL/4AF cases identified were further confirmed by cytogenetic and/or molecular analysis Finally, univariate analysis has been performed considering separately infants and children older than 1 year carrying a t(4;11) translocation and demonstrated that marker protein expression profiles present no statistically significant difference (data not shown). This finding was further confirmed and supported by similar analysis performed on populations of infants, children aged 1-9 years and children above 10 years, also in the latter case no statistically significant differences were present between groups.
Conclusions
Computational immunophenotypic data analysis
Flow-cytometry immunophenotypic monitoring is routinely applied to all ALLs at the moment of diagnosis since this analysis can be easily performed, needs relatively few starting material and gives immediately final results without any additional costs. However, up to now, immunophenotypic differences between leukemia subtypes have been mostly based on qualitative differences in expression profiles and on the definition of thresholds for single antigens making further analysis cumbersome. Recently, in an immunophenotypic study of myelodysplastic syndromes the question of numerically coding fluorescence signals for statistical analysis was overcome by computing fluorescent ratios between the percentage of cells expressing the marker and the intensity of the marker expression. 29 Our results demonstrate that: (i) key markers discriminating different leukemia phenotypes can be identified by univariate hypothesis testing from a data set of immunophenotypic markers described by two variables, one reflecting the intensity of expression (MESF) and the other the pattern of distribution (CV); (ii) subclasses among the groups of labeled samples can be detected by unsupervised clustering through Table 4 Classification performance, sensitivity, and selectivity of the 32 LDA classifiers created using increasing numbers of markers starting from the top discriminators in Table 3 Computational flow-cytometry analysis of pB-ALL subgroups De Zen et al multivariate PCA; (iii) different leukemia phenotypes can be confidentially diagnosed by a classification scheme (eg LDA) designed on a selected group of discriminating markers. This computational framework for immunophenotypic leukemia data analysis can represent a useful tool in exploring prospective data sets and maximizing the diagnostic potentials of flow cytometry.
Identification of MLL/AF4 immunophenotypic subgroup
Flow cytometry has also been used in several immunophenotypic studies to detect correlations between specific genetic aberrations and leukemia-associated phenotypes. 16, [30] [31] [32] In the most recent literature, the definition of an immunophenotypic common profile (CD19+, CD10À, CD15, and/or CD65+, NG2+) for all aberrations of samples with MLL is preferred. Interestingly, our analysis demonstrates that multivariate projection clusters MLL/AF4 individuals separately from samples with other MLL rearrangements. To our knowledge, this is the first time that a phenotypic heterogeneity is described among MLL+ cases and this finding seems to corroborate the hypothesis that different MLL partner genes induce distinct phenotypes and the experimental evidence represented by the different clinical outcomes. 16, [33] [34] [35] This MLL/AF4-specific pattern was not previously detected in gene expression profiling data even though preliminary results from a reexamination of the ALL database presented by Armstrong et al.
14 seem to confirm its presence (in preparation). The apparent different sensitivity in ALL subclass identification obtained by quantitative flow-cytometry analysis and gene expression microarray studies may be related to the ability of flow cytometry to measure not only expression quantity (MESF) levels that reflect the number of antibody molecules per cell, but also the homogeneity of expression (CV) or how many cells vary in the expression of a particular molecule. Undergoing developments of the current project include the enrichment of the database to enhance the robustness of the computational findings and the characterization of other leukemia groups with homogenous protein expression profiles.
